Evaluation Checklist for the Multidisciplinary Approach to Patients with Asthma or Suspected Asthma in United Airway Disease.

Purpose: To generate an evaluation checklist for the multidisciplinary approach to patients with asthma or suspected asthma.

Patients And Methods: This was a qualitative study based on a literature review and expert opinions. A multidisciplinary steering committee with knowledge and experience in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) was established and comprised two pneumologists, two allergologists, and two otorhinolaryngologists.

Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met?

Advances in knowledge about clinical features, physiology, and underlying immunology are leading to targeted therapies and a new era of therapies. Biological treatments for severe asthma have changed the way this disease is managed, especially in patients who do not respond adequately to conventional treatments with corticosteroids and bronchodilators. These treatments block the action of different molecules involved in the immune response and in the inflammation of the airways, bronchoconstriction, bronchial hyperresponsiveness, and excessive mucus production.

Is it possible to achieve remission in severe asthma? Retrospective analysis of a four-year response in a real-life cohort treated with mepolizumab.

Response to biologics in severe uncontrolled asthma (SUA) can be classified as super-responders, good responders, non-responders, and those achieving clinical remission. The aim of this study is to evaluate the long-term response to mepolizumab in patients with severe eosinophilic asthma and assesses the rate of asthma clinical remission over four years in a real-life setting. This is a single-center, observational, retrospective study was conducted at La Paz University Hospital (Madrid, Spain) from 2017 to 2022.